Aethlon Medical posts corporate presentation on Hemopurifier blood-filtration platform targeting cancer, viral threats, transplant

Aethlon Medical, Inc.

Aethlon Medical, Inc.

AEMD

0.00
  • Aethlon Medical highlighted the Hemopurifier platform, an extracorporeal blood filter designed to capture enveloped viruses and tumor-derived extracellular vesicles.
  • Reported 173 treatments across 44 patients with a favorable safety profile; oncology study in Australia completed two cohorts with cohort 3 enrolling.
  • Noted no dose-limiting toxicities or device-related serious adverse events at 7-day follow-ups; data readouts expected in 6-9 months.
  • Outlined cash of USD 5 million as of March 31, 2026; no outstanding debt; about 2,400,000 shares outstanding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.